FrancophonIA/ELRC3.0 huggingface dataset:
English: In a clinical trial with liraglutide as monotherapy, rates of hypoglycaemia reported with liraglutide were lower than rates reported for patients treated with active comparator (glimepiride).
Slovenian: V kliničnem preskušanju monoterapije z liraglutidom je bil delež hipoglikemij manjši med bolniki, ki so dobivali liraglutid, kot med bolniki, ki so dobivali primerjalno zdravilo (glimepirid).
English: Digoxin
Slovenian: Digoksin
English: Press the dose button to inject until 0 mg lines up with the pointer.
Slovenian: Pritisnite potisni gumb in injicirajte zdravilo, dokler se vrednost 0 mg ne poravna s kazalnikom.
English: Significantly more patients achieved HbA1c below 7% with liraglutide compared with placebo (52.8% vs 19.5%).
Slovenian: Z liraglutidom je v primerjavi s placebom značilno več bolnikov doseglo znižanje HbA1c pod 7 % (52,8 % v primerjavi z 19,5 %).
English: Animal studies have shown that the transfer of liraglutide and metabolites of close structural relationship into milk is low.
Slovenian: Študije na živalih so pokazale majhno prehajanje liraglutida in njegovih presnovkov s podobno zgradbo v mleko.
English: • Increased pulse
Slovenian: • zvišan srčni utrip
English: Disodium phosphate dihydrate, propylene glycol, phenol, water for injections
Slovenian: natrijev hidrogenfosfat dihidrat, propilenglikol, fenol in vodo za injekcije.
English: p<0.001 for non-inferiority p=0.005 for superiority
Slovenian: 95 % IZ [0,78; 0,97] p<0,001 za neinferiornost p=0,005 za superiornost
English: Few patients treated with liraglutide reported at least one episode of severe diarrhoea.
Slovenian: Pri nekaterih bolnikih, ki so se zdravili z liraglutidom, se je vsaj enkrat pojavila huda driska.
English: The pen is designed to be used with NovoFine or NovoTwist disposable needles.
Slovenian: Injekcijski peresnik je namenjen za uporabo z iglami NovoFine ali NovoTwist za enkratno uporabo.
English: OTHER
Slovenian: O
English: After that, you may see a drop liraglutide at the needle tip.
Slovenian: Na konici igle boste morda videli kapljico liraglutida.
English: When the needle is covered, carefully push the outer needle cap completely on. Then unscrew the needle.
Slovenian: Ko je igla pokrita, zunanji pokrovček previdno do konca potisnite nanjo.
English: No severe hypoglycaemic episodes occurred in the liraglutide treatment group.
Slovenian: V terapevtski skupini z liraglutidom ni prišlo do pojava hudih hipoglikemij.
English: Renal impairment Renal failure acute
Slovenian: Bolezni sečil okvara ledvic, akutna odpoved ledvic
English: In vitro, liraglutide has shown very low potential to be involved in pharmacokinetic interactions with other active substances related to cytochrome P450 and plasma protein binding.
Slovenian: 4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij V poskusih in vitro je bila ugotovljena zelo majhna možnost medsebojnega farmakokinetičnega delovanja liraglutida in drugih učinkovin, ki bi bilo povezano s citokromom P450 ali vezavo na beljakovine v plazmi.
English: Liraglutide monotherapy for 52 weeks resulted in statistically significant and sustained reductions in HbA1c compared with glimepiride 8 mg (-0.84% for 1.2 mg, -1.14% for 1.8 mg vs -0.51% for comparator) in patients previously treated with either diet and exercise or OAD monotherapy at no more than half-maximal dose (Table 2).
Slovenian: Monoterapija 52-tedensko zdravljenje z liraglutidom v monoterapiji je povzročilo statistično pomembno in trajno zmanjšanje vrednosti HbA1c v primerjavi z glimepiridom v odmerku 8 mg (-0,84 % pri odmerku 1,2 mg in -1,14 % pri odmerku 1,8 mg v primerjavi z -0,51 % pri primerjalnem zdravilu) pri bolnikih, ki so se predhodno zdravili z dieto in telesno vadbo ali s peroralnim antidiabetikom v monoterapiji z ne več kot polovico največjega odmerka (preglednica 2).
English: • A delay in the emptying of the stomach.
Slovenian: • zakasnelo praznjenje želodca
English: Injection site reactions have been reported in approximately 2% of patients receiving Victoza in longterm (26 weeks or longer) controlled trials.
Slovenian: Victoza v dolgotrajnih kontroliranih preskušanjih (26 tednov ali dlje).
English: This usually goes away over time.
Slovenian: • driska; ponavadi sčasoma izgine
English: Always remove the needle after each injection, and store your pen without a needle attached.
Slovenian: Po vsakem injiciranju odstranite iglo in injekcijski peresnik shranite brez nameščene igle.
English: Solution for injection.
Slovenian: raztopina za injiciranje
English: Figure 1: Kaplan Meier plot of time to first MACE - FAS population
Slovenian: Slika 1: Kaplan Meier-jeva krivulja časa do prvega pojava pomembnih srčno-žilnih neželenih dogodkov - analiza podatkov celotne populacije (FAS (Full Analysis Set) Population)
English: Liraglutide reduces body weight and body fat mass through mechanisms involving reduced hunger and lowered energy intake, GLP-1 is a physiological regulator of appetite and food intake, but the exact mechanism of action is not entirely clear.
Slovenian: GLP-1 je fiziološki regulator apetita in vnosa hrane, vendar pa natančen mehanizem delovanja ni v celoti znan.
English: Very common: may affect more than 1 in 10 people
Slovenian: Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov
English: Few cases of cholelithiasis (0.4%) and cholecystitis (0.1%) have been reported during long-term, controlled phase 3a clinical trials with liraglutide.
Slovenian: Med dolgotrajnimi, kontroliranimi kliničnimi preskušanji z liraglutidom faze 3a so poročali o nekaj primerih holelitiaze (0,4 %) in holecistitisa (0,1 %).
English: These trials included 3,978 exposed patients with type 2 diabetes mellitus (2,501 patients treated with liraglutide), 53.7% men and 46.3% women, 797 patients (508 treated with liraglutide) were ≥65 years of age and 113 patients (66 treated with liraglutide) were ≥75 years of age.
Slovenian: V teh preskušanjih je bilo zdravljenju izpostavljenih 3.978 bolnikov s sladkorno boleznijo tipa 2 (2.501 se jih je zdravilo z liraglutidom), od tega 53,7 % moških in 46,3 % žensk.
English: The need for treatment intensification with insulin was reduced by 48% with liraglutide vs placebo in insulin-naive patients at baseline (HR 0.52 [0.48;
Slovenian: Potreba po stopnjevanju zdravljenja z insulinom pri bolnikih, ki v izhodišču še niso bili zdravljeni z insulinom, je bila pri liraglutidu zmanjšana do 48 % v primerjavi s placebom (razmerje ogroženosti 0,52 [0,48; 0,57]).
English: A mean increase in heart rate from baseline of 2 to 3 beats per minute has been observed with liraglutide in long-term clinical trials including LEADER.
Slovenian: V dolgotrajnih kliničnih preskušanjih, vključno s preskušanjem LEADER, je bilo opaženo povprečno povečanje srčnega utripa za 2 do 3 utripe na minuto v primerjavi z izhodiščem.
English: Thyroid adverse events, such as goitre, have been reported in clinical trials and in particular in patients with pre-existing thyroid disease.
Slovenian: Bolezen ščitnice V kliničnih preskušanjih so bili opisani ščitnični neželeni učinki, kot je golša, in to zlasti pri bolnikih z obstoječo boleznijo ščitnice.
English: Cardiovascular death
Slovenian: Smrt zaradi srčno-žilnih zapletov
English: In the insulin degludec + liraglutide arm, the insulin dose was reduced by 20% in order to minimize the risk of hypoglycaemia.
Slovenian: Da bi zmanjšali tveganje za hipoglikemijo, so v skupini z insulinom degludek + liraglutidom odmerek insulina zmanjšali za 20 %.
English: The reductions in HbA1c and superiority vs sitagliptin observed after 26 weeks of liraglutide treatment (1.2 mg and 1.8 mg) were sustained after 52 weeks of treatment (-1.29% and -1.51% vs -0.88%, p<0.0001).
Slovenian: Znižanje HbA1c in superiornost v primerjavi s sitagliptinom, opažena po 26 tednih zdravljenja z liraglutidom (1,2 mg in 1,8 mg), sta se ohranila tudi po 52 tednih zdravljenja (-1,29 % in -1,51 % v prim.
English: Liraglutide stimulates insulin secretion in a glucosedependent manner.
Slovenian: Liraglutid spodbudi izločanje insulina odvisno od koncentracije glukoze.
English: Keep the pen cap on in order to protect from light.
Slovenian: Injekcijski peresnik naj bo pokrit s pokrovčkom za zagotovitev zaščite pred svetlobo.
English: For use by one person only
Slovenian: Izključno za uporabo pri enem samem bolniku.
English: The analysis of time to first microvascular event for liraglutide vs placebo had a HR of 0.84 [0.73, 0.97].
Slovenian: Pri analizi časa do prvega mikrovaskularnega dogodka je bilo razmerje ogroženosti 0,84 [0,73, 0,97] za liraglutid v primerjavi s placebom.
English: The use of Victoza is not recommended if you are on dialysis.
Slovenian: Uporaba zdravila Victoza ni priporočljiva, če se zdravite z dializo.
English: This is more likely to happen if you also take a sulfonylurea or insulin.
Slovenian: Pojav teh opozorilnih znakov je bolj verjeten, če uporabljate tudi sulfonilsečnino ali insulin.
English: 1 pen 2 pens 3 pens 5 pens 10 pens
Slovenian: 1 injekcijski peresnik 2 injekcijska peresnika 3 injekcijski peresniki 5 injekcijskih peresnikov 10 injekcijskih peresnikov
English: Turn the dose selector in either direction until 0.6 mg or 1.2 mg lines up with the pointer.
Slovenian: Izbirnik odmerka vrtite v ustrezno smer, dokler se s kazalnikom ne poravna vrednost 0,6 mg ali 1,2 mg. Injicirajte odmerek.
English: Conversely, during hypoglycaemia liraglutide diminishes insulin secretion and does not impair glucagon secretion.
Slovenian: Nasprotno med hipoglikemijo liraglutid zmanjša izločanje insulina, ne zmanjša pa izločanja glukagona.
English: Greater proportions of patients treated with liraglutide experienced transient nausea vs patients treated with sitagliptin (20.8% and 27.1% for liraglutide vs 4.6% for sitagliptin).
Slovenian: zdravljenimi s sitagliptinom (20,8 % in 27,1 % pri liraglutidu v prim.
English: This is to make sure that you get your full dose.
Slovenian: Tako zagotovite injiciranje celotnega odmerka.
English: 1 ml contains 6 mg of liraglutide.
Slovenian: 1 ml vsebuje 6 mg liraglutida.
English: Other side effects
Slovenian: Drugi neželeni učinki
English: Estimated maximum liraglutide concentration was 9.4 nmol/l (mean body weight approximately 73 kg) for a subcutaneous single dose of liraglutide 0.6 mg. At 1.8 mg liraglutide, the average steady state concentration of liraglutide (AUCτ/24) reached approximately 34 nmol/l (mean body weight approximately 76 kg).
Slovenian: Ocenjena največja koncentracija liraglutida pri enkratnem subkutanem 0,6-miligramskem odmerku liraglutida je bila 9,4 nmol/l (pri povprečni telesni masi približno 73 kg).
English: You may experience nausea, vomiting or diarrhoea.
Slovenian: Pojavi se lahko siljenje na bruhanje, bruhanje ali driska.
English: Increased amylase* * From controlled phase 3b and 4 clinical trials only where they were measured.
Slovenian: * Podatki iz tistih kliničnih preskušanj faze 3b in 4, kjer so spremljali koncentracijo encimov.
English: (74.2% vs 45.5%, p<0.0001), as well as the HbA1c target below or equal 6.5% (54.6% vs 26.2%, p<0.0001).
Slovenian: Pri uporabi liraglutida je statistično značilno več bolnikov doseglo vrednost HbA1c, manjšo od 7 %, kot pri uporabi liksisenatida (74,2 % v primerjavi s 45,5 %, p<0,0001), prav tako pa tudi ciljno vrednost HbA1c, manjšo ali enako 6,5 % (54,6 % v primerjavi s 26,2 %, p<0,0001).
English: Select your dose Always check that the pointer lines up with 0 mg.
Slovenian: Vedno se prepričajte, da je kazalnik poravnan z vrednostjo 0 mg.
English: Victoza is used with other medicines for diabetes when they are not enough to control your blood sugar levels.
Slovenian: Zdravilo Victoza se uporablja skupaj z drugimi zdravili za zdravljenje sladkorne bolezni (če ta zdravila ne zadostujejo za ureditev koncentracije krvnega sladkorja), in sicer s:
English: Non-lethal thyroid C-cell tumours were seen in 2-year carcinogenicity studies in rats and mice.
Slovenian: V dveletni študiji kancerogenosti so pri podganah in miših opazili tumorje parafolikularnih celic ščitnice, ki niso bili smrtni.
English: Patients treated with liraglutide had a significant decrease in body weight compared to that of patients treated with sitagliptin (-2.9 kg and -3.4 kg vs -1.0 kg, p<0.0001).
Slovenian: Bolnikom, ki so prejemali liraglutid, se je telesna masa značilno bolj znižala kot bolnikom, ki so prejemali sitagliptin (-2,9 kg in -3,4 kg v prim.
English: Do not use the pen if a drop of liraglutide still does not appear.
Slovenian: Če se kapljica liraglutida še vedno ne pojavi, ne uporabite injekcijskega peresnika.
English: Serious side effects
Slovenian: Resni neželeni učinki
English: Rare: may affect up to 1 in 1,000 people
Slovenian: Redki: pojavijo se lahko pri največ 1 od 1.000 bolnikov
English: • oral antidiabetics (such as metformin, pioglitazone, sulfonylurea, sodium-glucose cotransporter
Slovenian: • peroralnimi antidiabetiki (kot so metformin, pioglitazon, sulfonilsečnine, zaviralci natrijevih glukoznih koprenašalcev 2 (zaviralci SGLT2)) in/ali insulinom.
English: No dose adjustment is required for adolescents and children aged 10 years and above.
Slovenian: Pediatrična populacija Mladostnikom in otrokom, starim 10 let ali več, odmerka ni treba prilagoditi.
English: • Keep your pen away from dust, dirt and all kinds of liquids.
Slovenian: • Hranite ga na čistem mestu, kjer ni prahu, umazanije ali tekočin.
English: Gender had no clinically meaningful effect on the pharmacokinetics of liraglutide based on the results of population pharmacokinetic data analysis of male and female patients and a pharmacokinetic study in healthy subjects.
Slovenian: Glede na rezultate populacijske farmakokinetične analize podatkov bolnikov in bolnic ter rezultate farmakokinetične študije zdravih oseb spol ne vpliva klinično pomembno na farmakokinetiko liraglutida.
English: • Headache
Slovenian: • glavobol
English: Very rare: may affect up to 1 in 10,000 people
Slovenian: Zelo redki: pojavijo se lahko pri največ 1 od 10.000 bolnikov
English: The study population included patients ≥65 years (n=4,329) and ≥75 years (n=836) and patients with mild (n=3,907), moderate (n=1,934) or severe (n=224) renal impairment.
Slovenian: Populacija v študiji je vključevala bolnike ≥ 65 let (n = 4.329) in ≥ 75 let
English: Improved first and second phase insulin secretion after 52 weeks treatment with liraglutide was demonstrated in a subset of patients with type 2 diabetes (n=29).
Slovenian: Po 52 tednih zdravljenja z liraglutidom so pri skupini bolnikov s sladkorno boleznijo tipa 2 (n = 29) ugotovili izboljšano prvo in drugo stopnjo izločanja insulina.
English: Headache and nasopharyngitis were also common.
Slovenian: Pogosta sta bila tudi glavobol in nazofaringitis.
English: • Fasting plasma glucose
Slovenian: • Koncentracija glukoze v plazmi na tešče
English: Non-cardiovascular death
Slovenian: Smrt, ki ni posledica srčno-žilnega zapleta
English: The pen is designed to be used with NovoFine or NovoTwist disposable injection needles up to a length of 8 mm and as thin as 32G (0.25/0.23 mm).
Slovenian: 8 mm in ne tanjšimi kot 32G (0,25/0,23 mm).
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED PEN LABEL
Slovenian: PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
English: Contact your doctor if you have any questions or concerns.
Slovenian: Če imate kakšna vprašanja ali vas kaj skrbi, se posvetujte z zdravnikom.
English: Lisinopril median tmax was delayed from 6 h to 8 h with liraglutide.
Slovenian: Mediani čas do največje koncentracije lizinoprila (tmax) se je pri hkratnem zdravljenju z liraglutidom podaljšal s 6 na 8 ur.
English: Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited.
Slovenian: Ko je torej koncentracija glukoze v krvi velika, se izločanje insulina poveča, izločanje glukagona pa zmanjša.
English: One pre-filled pen contains 18 mg liraglutide in 3 ml.
Slovenian: En napolnjen injekcijski peresnik vsebuje 18 mg liraglutida v 3 ml.
English: 1 ml solution for injection contains 6 mg liraglutide.
Slovenian: 1 mililiter raztopine za injiciranje vsebuje 6 mg liraglutida.
English: No dose adjustment is required for patients with mild, moderate or severe renal impairment.
Slovenian: Okvara ledvic Pri zdravljenju bolnikov z blago, zmerno ali hudo okvaro ledvic prilagoditev odmerka ni potrebna.
English: Switching patients from sitagliptin to liraglutide after 52 weeks of treatment resulted in additional and statistically significant reduction in HbA1c (-0.24% and -0.45%, 95% CI: -0.41 to -0.07 and -0.67 to -0.23) at week 78, but a formal control group was not available.
Slovenian: Prehod bolnikov s sitagliptina na liraglutid po 52 tednih zdravljenja je povzročil dodatno in statistično značilno znižanje HbA1c (-0,24 % in -0,45 %, 95 % IZ: -0,41 do -0,07
English: Age had no clinically relevant effect on the pharmacokinetics of liraglutide based on the results from a pharmacokinetic study in healthy subjects and population pharmacokinetic data analysis of patients (18 to 80 years).
Slovenian: Glede na rezultate farmakokinetične študije zdravih oseb in populacijske farmakokinetične analize podatkov bolnikov (starih od 18 do 80 let) starost ne vpliva klinično pomembno na farmakokinetiko liraglutida.
English: • Proportion of patients achieving reductions in HbA1c Liraglutide alone resulted in a statistically significant greater proportion of patients achieving HbA1c ≤6.5% at 52 weeks compared with patients receiving glimepiride (37.6% for 1.8 mg and 28.0% for 1.2 mg vs 16.2% for comparator).
Slovenian: • Delež bolnikov, pri katerih se je vrednost HbA1c zmanjšala Pri uporabi liraglutida samega je bil delež bolnikov, ki so po 52 tednih dosegli vrednost HbA1c ≤ 6,5 %, statistično značilno večji, kot pri bolnikih, ki so prejemali glimepirid (37,6 % pri odmerku
English: - if you are allergic to liraglutide or any of the other ingredients of this medicine (listed in section
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo Victoza Ne uporabljajte zdravila Victoza, - če ste alergični na liraglutid ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: Severe hypoglycaemia has primarily been observed when combined with a sulfonylurea.
Slovenian: Huda hipoglikemija je bila opisana predvsem pri bolnikih, ki so hkrati prejemali sulfonilsečnino.
English: You can select doses of 0.6 mg, 1.2 mg and 1.8 mg.
Slovenian: Izberete lahko odmerke 0,6 mg, 1,2 mg in 1,8 mg. Injekcijski peresnik je namenjen za uporabo z iglami
English: Liraglutide is extensively bound to plasma proteins (>98%).
Slovenian: Liraglutid je v veliki meri vezan na beljakovine v plazmi
English: Name and address of the manufacturer of the biological active substance
Slovenian: Ime in naslov proizvajalca biološke učinkovine Novo Nordisk A/S
English: Add-on to metformin (2,000 mg/day) + rosiglitazone (4 mg twice daily) Liraglutide 1.2 mg 177 8.48
Slovenian: Dodatek k zdravljenju z metforminom (2.000 mg/dan) + rosiglitazonom (4 mg dvakrat na dan) liraglutid 1,2 mg liraglutid 1,8 mg placebo
English: This medicine contains less than 1 mmol sodium (23 mg) per dose.
Slovenian: Zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na odmerek, kar v bistvu pomeni "brez natrija".
English: • Inflamed gallbladder
Slovenian: • vnetje žolčnika
English: Victoza 6 mg/ml injection Liraglutide
Slovenian: Victoza 6 mg/ml injekcija liraglutid za subkutano uporabo
English: 1 ml of solution contains 6 mg of liraglutide*.
Slovenian: 1 ml raztopine vsebuje 6 mg liraglutida*.
English: Headache Dizziness
Slovenian: Okvara ledvic
English: Tmax was delayed by 1.5 h with liraglutide for both compounds.
Slovenian: Čas do največje koncentracije (tmax) se je pri sočasnem zdravljenju z liraglutidom pri obeh učinkovinah podaljšal za 1,5 ure.
English: • Immunogenicity
Slovenian: • Imunogenost
English: In a double-blind study comparing the efficacy and safety of Victoza 1.8 mg versus placebo as add-on to metformin ± insulin in adolescents and children aged 10 years and above with type 2 diabetes, Victoza was superior to placebo treatment in reducing HbA1c after 26 weeks (-1.06, [-1.65, 0.46]).
Slovenian: Izvedli so dvojno slepo študijo za primerjavo učinkovitosti in varnosti 1,8 mg zdravila Victoza v primerjavi s placebom kot dodatka metforminu ± insulinu pri mladostnikih in otrocih, starih 10 let ali več, s sladkorno boleznijo tipa 2; v tej študiji je bilo zdravilo Victoza po 26 tednih superiorno placebu, kar zadeva znižanje HbA1c (-1,06 [-1,65, 0,46]).
English: Atorvastatin Cmax was decreased by 38% and median tmax was delayed from 1 h to 3 h with liraglutide.
Slovenian: Pri zdravljenju z liraglutidom se je največja koncentracija atorvastatina (Cmax) zmanjšala za 38 %, mediani čas do največje koncentracije (tmax) pa se je podaljšal z 1 na 3 ure.
English: Liraglutide exposure was lowered by 33%, 14%, 27% and 26% in patients with mild (creatinine clearance, CrCl 50-80 ml/min), moderate (CrCl 30-50 ml/min), and severe (CrCl <30 ml/min) renal impairment and in end-stage renal disease requiring dialysis, respectively.
Slovenian: Pri bolnikih z blago okvaro ledvic (očistek kreatinina 50-80 ml/min) je bila izpostavljenost liraglutidu manjša za 33 %, z zmerno okvaro ledvic (očistek kreatinina 30-50 ml/min)
English: Hypoglycaemia Anorexia
Slovenian: Bolezni imunskega sistema anafilaktičn a reakcija
English: In an open label trial comparing the efficacy and safety of liraglutide (1.2 mg and 1.8 mg) and sitagliptin (a DPP-4 inhibitor, 100 mg) in patients inadequately controlled on metformin therapy (mean HbA1c 8.5%), liraglutide at both doses was statistically superior to sitagliptin treatment in reducing HbA1c after 26 weeks (-1.24%, -1.50% vs -0.90%, p<0.0001).
Slovenian: V odprtem preskušanju, ki je primerjalo učinkovitost in varnost liraglutida (1,2 mg in 1,8 mg) in sitagliptina (zaviralca DPP-4, odmerek 100 mg) pri bolnikih, nezadostno urejenih z metforminom (srednji HbA1c 8,5 %), je bil liraglutid v obeh odmerkih statistično superioren v primerjavi s sitagliptinom, kar zadeva znižanje HbA1c po 26 tednih (-1,24 %, -1,50 % v prim.
English: Liraglutide 1.8 mg 246 8.19
Slovenian: Monoterapija liraglutid 1,2 mg liraglutid 1,8 mg glimepirid 8 mg/dan 248 8,23
English: HR: 0.87 95% CI [0.78; 0.97]
Slovenian: z -0,88 %, p < 0,0001).
English: Special populations
Slovenian: Posebne skupine bolnikov
English: Liraglutide did not change the overall exposure of atorvastatin to a clinically relevant degree following single dose administration of atorvastatin 40 mg.
Slovenian: Liraglutid ni spremenil celotne izpostavljenosti griseofulvinu po enkratnem odmerku 500 mg griseofulvina.
English: In an open label trial comparing the efficacy and safety of liraglutide 1.8 mg with lixisenatide 20 mcg in 404 patients inadequately controlled on metformin therapy (mean HbA1c 8.4%), liraglutide was superior to lixisenatide in reducing HbA1c after 26 weeks of treatment (-1.83% vs -1.21%, p<0.0001).
Slovenian: V odprtem preskušanju, ki je primerjalo učinkovitost in varnost liraglutida v odmerku 1,8 mg z liksisenatidom v odmerku 20 µg pri 404 bolnikih, nezadostno urejenih pri zdravljenju z metforminom (srednja vrednost HbA1c 8,4 %), se je liraglutid pri zmanjšanju vrednosti HbA1c po 26 tednih zdravljenja izkazal za superiornega v primerjavi z liksisenatidom (-1,83 % v primerjavi z -1,21 %,
English: Hypoglycaemia
Slovenian: Hipoglikemija
English: Addition of liraglutide resulted in a statistically significantly greater reduction of HbA1c (-0.73% for liraglutide vs -0.40% for comparator) and body weight (-3.03 vs 0.72 kg).
Slovenian: (-0,73 % pri liraglutidu v primerjavi z -0,40 % pri primerjalnem zdravilu) in telesne mase (-3,03 v primerjavi z 0,72 kg).
English: The incidence of withdrawal due to adverse reactions was 7.8% for liraglutide-treated patients and 3.4% for comparator-treated patients in the long-term controlled trials (26 weeks or longer).
Slovenian: V dolgotrajnih kontroliranih preskušanjih (26 tednov ali dlje) je bilo zaradi neželenih učinkov zdravljenje prekinjeno pri 7,8 % bolnikov, ki so se zdravili z liraglutidom, in pri 3,4 % bolnikov, ki so prejemali primerjalno zdravilo.